Abstract:Simple Summary TKI have vastly improved long-term outcomes for patients with CML, although it is still hard for a proportion of patients to obtain ideal molecular responses. Advances in NGS technology have enabled the incorporation of somatic mutation profiles in classification and prognostication. With an increased focus on achieving deep molecular responses, we try to explore the risk conferred by additional genomic lesions other than BCR proportion ABL through NGS technology. We also figure out how clinical characteristics, distinct TKI options and risk scores influence the achieving of molecular responses. This research has the potential to lay the foundation for improved risk classification according to clinical and genomic risk and to enable more precise early identification of TKI. A proportion of patients with somatic variants show resistance or intolerance to TKI therapy, indicating additional mutations other than BCR proportion ABL1 may lead to TKI treatment failure or disease progression. We retrospectively evaluated 151 CML patients receiving TKI therapy and performed next-generation sequencing (NGS) analysis of 22 CML patients at diagnosis to explore the mutation spectrum other than BCR proportion ABL1 affecting the achievement of molecular responses. The most frequently mutated gene was ASXL1 (40.9%). NOTCH3 and RELN mutations were only carried by subjects failing to achieve a major molecular response (MMR) at 12 months. The distribution frequency of ASXL1 mutations was higher in the group that did not achieve MR4.0 at 36 months (p = 0.023). The achievement of MR4.5 at 12 months was adversely impacted by the presence of >2 gene mutations (p = 0.024). In the analysis of clinical characteristics, hemoglobin concentration (HB) and MMR were independent factors for deep molecular response (DMR), and initial 2GTKI therapy was better than 1GTKI in the achievement of molecular response. For the scoring system, we found the ELTS score was the best for predicting the efficacy of TKI therapy and the Socal score was the best for predicting mutations other than BCR proportion ABL.

Genomic Mechanisms Influencing Outcome in Chronic Myeloid Leukemia

Beyond BCR::ABL1-The Role of Genomic Analyses in the Management of CML

Mutational landscape of chronic myeloid leukemia: more than a single oncogene leukemia

Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia—From Molecular Mechanisms to Clinical Relevance

Genetic landscape of chronic myeloid leukemia

Pharmacogenomics of Impaired Tyrosine Kinase Inhibitor Response: Lessons Learned From Chronic Myelogenous Leukemia

Mutations in myeloid transcription factors and activated signaling genes predict chronic myeloid leukemia outcomes

Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy

BCR-ABL1 Tyrosine Kinase Complex Signaling Transduction: Challenges to Overcome Resistance in Chronic Myeloid Leukemia

Control of Ph+ and additional chromosomal abnormalities in chronic myeloid leukemia by tyrosine kinase inhibitors

Clinical Insights into Structure, Regulation, and Targeting of ABL Kinases in Human Leukemia

BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid Leukemia

Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia

Targeted Next-Generation Sequencing Identifies Additional Mutations Other than <i>BCR proportion ABL</i> in Chronic Myeloid Leukemia Patients: A Chinese Monocentric Retrospective Study

The impact of the BCR-ABL oncogene in the pathology and treatment of chronic myeloid leukemia

Insights into existing and futuristic treatment approach for chronic myeloid leukaemia

Differential genomics and transcriptomics between tyrosine kinase inhibitor-sensitive and -resistant BCR-ABL-dependent chronic myeloid leukemia

Detection of FLT3/ITD, JAK2(V617F) and NPM1 gene mutations in chronic myelomonocytic leukemia

Pharmacotherapeutic Options for Philadelphia Chromosome-Positive CML

Resistance mutations in CML and how we approach them

Integrated functional genomic screening to bypass TKI resistance in chronic myeloid leukemia